Kisspeptin-10
updated
Kisspeptin-10 is the 10-amino-acid active fragment of kisspeptin, a natural brain peptide that switches on the reproductive hormone cascade; no FDA-approved kisspeptin-10 drug exists. Sellers tie it to sexual desire and fertility. In healthy men it acutely raised LH, and a continuous infusion lifted testosterone from 16.6 to 24.0 nmol/L, but the headline sexual-desire and IVF trials used kisspeptin-54, a different form, and no study measured symptom relief or pregnancy with kisspeptin-10. Graded B for those direct human hormone responses, not for fertility or desire outcomes.
KISS1 receptor agonist peptide
- Amidated 10-amino-acid KISS1 fragment
- Direct human LH and testosterone studies exist
- IVF and HSDD findings largely come from kisspeptin-54
- No FDA-approved kisspeptin-10 drug
Is kisspeptin-10 the same as kisspeptin-54?
Kisspeptin-10 and kisspeptin-54 activate the same KISS1 receptor but differ in length and pharmacology. Results from the longer peptide do not provide kisspeptin-10 dosing, exposure, efficacy, or safety data.
Kisspeptin-10 is the amidated C-terminal decapeptide that retains receptor activity. Kisspeptin-54 is a longer endogenous form. Route, dose, duration, and breakdown can differ even when two peptides share a receptor.
| Question | Direct KP-10 evidence | Mostly KP-54 evidence |
|---|---|---|
| Acute LH and testosterone response | Yes | Also studied |
| IVF oocyte-maturation trigger | Not established by the cited KP-10 studies | Yes |
| Randomized HSDD brain-response studies | Not established | Yes |
source: KP-10 · LH pulse physiology, George JT et al. Journal of Clinical Endocrinology and Metabolism, 2011.
source: KP-54 · IVF study, different peptide form, Jayasena CN et al. Journal of Clinical Investigation, 2014.
What has kisspeptin-10 actually done in people?
Kisspeptin-10 acutely increased LH secretion and, in selected male studies, testosterone. The experiments did not measure symptom relief, pregnancy rates, libido treatment, or sustained testosterone benefit.
The response is context-dependent. Men and women, and women at different cycle phases, did not respond identically. Endocrine state matters because kisspeptin acts upstream of GnRH, LH, FSH, and gonadal hormone production.
Does it raise testosterone?
Testosterone increased acutely in the studied men, but the experiments did not measure durable effects or symptom improvement. WADA separately classifies kisspeptin as a testosterone-stimulating peptide in males.
source: KP-10 · LH pulse physiology
source: KP-10 · diabetes endocrine study, George JT et al. Clinical Endocrinology, 2013.
source: WADA 2026 · kisspeptin in males, World Anti-Doping Agency, effective 1 January 2026.
Does it improve IVF outcomes?
The best-known maturation-trigger work used kisspeptin-54. It supplies no dose, exposure, efficacy, or safety data for a kisspeptin-10 protocol.
source: KP-10 · LH pulse physiology
source: KP-10 · diabetes endocrine study
source: KP-10 · men and women physiology, Chan YM et al. Journal of Clinical Investigation, 2012.
How does kisspeptin-10 affect reproductive hormones?
Kisspeptin-10 activates KISS1R on GnRH neurons, which can drive GnRH release and downstream LH and FSH secretion. Human studies measured the resulting LH and testosterone changes.
This is an upstream endocrine intervention. The same signal can behave differently with sex, cycle phase, gonadal status, diabetes, hypothalamic disease, and repeated exposure.
Can it bypass a nonfunctioning pituitary or gonad?
The cited studies do not show that. A response requires enough intact downstream reproductive-axis function, and the experiments were designed to probe physiology rather than treat every cause of hypogonadism or infertility.
source: KP-10 · diabetes endocrine study
source: KP-10 · LH pulse physiology
source: KP-10 · men and women physiology
What safety questions remain?
Short human physiology studies cannot define repeated-use safety, pregnancy risk, effects on cycle timing, ovarian response, or consequences of sustained reproductive-axis stimulation. Compounded products add route and quality uncertainty.
- Hormone-axis effects: cycle changes, altered gonadotropins, and sex-steroid changes are pharmacologic effects, not incidental noise.
- Pregnancy and fertility treatment: the exact peptide, timing, and monitoring matter; research on KP-54 is not a safety label for KP-10.
- Product and route: FDA cites inadequate route-specific safety information plus impurity and immunogenicity concerns.
source: KP-10 · LH pulse physiology
source: KP-10 · men and women physiology
source: FDA safety page · route and impurity gaps, US Food and Drug Administration.
Is kisspeptin-10 an FDA-approved treatment?
The cited FDA records list no approved kisspeptin-10 product. FDA lists compounding safety concerns, and WADA prohibits kisspeptin and agonist analogues as testosterone-stimulating peptides in males.
The cited clinical studies used monitored research protocols and did not test a retail research-vial formulation.
source: FDA safety page · route and impurity gaps
source: WADA 2026 · kisspeptin in males
Studies and sources
KP-10 · LH pulse physiology
Human endocrine physiology study
George JT et al. Journal of Clinical Endocrinology and Metabolism, 2011.
Intravenous kisspeptin-10 produced dose-dependent luteinizing-hormone responses and increased LH pulse frequency in healthy men. A prolonged infusion also increased circulating testosterone under the study conditions. The study measured short-term hormones, not fertility, sexual function, muscle, or long-term safety.
- Participants / model
- Healthy adult men
- Treatment
- Acute and continuous intravenous kisspeptin-10 under research protocols
- Follow-up
- Hours
- Study design
- Dose-response human physiology experiments
The study reported hormone changes without symptom or fertility outcomes.
Read the original sourceKP-10 · diabetes endocrine study
Human physiology study
George JT et al. Clinical Endocrinology, 2013.
Kisspeptin-10 stimulated LH and testosterone secretion in men with type 2 diabetes and mild biochemical hypogonadism, showing that the hypothalamic-pituitary-gonadal axis could respond acutely. It did not test symptom improvement or repeated treatment.
- Participants / model
- Men with type 2 diabetes and mild biochemical hypogonadism
- Treatment
- Research administration of kisspeptin-10
- Follow-up
- Acute endocrine assessment
- Study design
- Human mechanistic study
KP-10 · men and women physiology
Human endocrine study
Chan YM et al. Journal of Clinical Investigation, 2012.
Responses to kisspeptin-10 differed by sex and menstrual-cycle phase, so one acute response did not describe every study group.
- Participants / model
- Healthy men and women studied across menstrual-cycle phases
- Treatment
- Intravenous kisspeptin-10
- Follow-up
- Acute sampling
- Study design
- Controlled human physiology experiments
KP-54 · IVF study, different peptide form
Human fertility study
Jayasena CN et al. Journal of Clinical Investigation, 2014.
Kisspeptin-54 triggered oocyte maturation in women undergoing IVF. The study used the longer 54-amino-acid form and supplies no equivalent dosing, exposure, efficacy, or safety data for kisspeptin-10.
- Participants / model
- Women undergoing IVF
- Treatment
- Kisspeptin-54 trigger
- Study design
- Clinical fertility study
Kisspeptin-54 is a different peptide form from kisspeptin-10.
Read the original sourceFDA safety page · route and impurity gaps
FDA safety communication
US Food and Drug Administration.
FDA lists kisspeptin-10 in its 503A category-2 safety table and cites immunogenicity, peptide-impurity, API-characterization, and limited route-specific safety information.
- Study design
- Agency safety summary
WADA 2026 · kisspeptin in males
Sports rule
World Anti-Doping Agency, effective 1 January 2026.
Kisspeptin and its agonist analogues are listed under testosterone-stimulating peptides in males, prohibited at all times for covered athletes.
- Study design
- Binding sport rule for covered athletes
Why is Kisspeptin-10 in B tier?
B reflects direct human studies showing acute LH and testosterone responses to kisspeptin-10. Fertility-trigger and sexual-desire outcomes come mainly from kisspeptin-54 and do not establish routine kisspeptin-10 treatment.
read Kisspeptin-10 in the reptides guide, chapter 51: 9 pages, free to read.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.